Credit Suisse on Prometheus (RXDX): 'Roivant’s Ph2b UC Results Support Anti-TL1A Approach; Prometheus’ PRA023 Maintains Best-in-Class Profile'
Go back to Credit Suisse on Prometheus (RXDX): 'Roivant’s Ph2b UC Results Support Anti-TL1A Approach; Prometheus’ PRA023 Maintains Best-in-Class Profile'| (NASDAQ: ROIV) | Delayed: 36.30 -0.54 (1.47%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $36.84 | 52 Week High | $ | |||
| Open | $37.03 | 52 Week Low | $ | |||
| Day High | $37.18 | P/E | N/A | |||
| Day Low | $36.23 | EPS | $ | |||
| Volume | 6,185,594 | |||||
| IGNYTA (NASDAQ: RXDX) | Delayed: 199.92 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $199.92 | 52 Week High | $15.20 | |||
| Open | $10.02 | 52 Week Low | $4.15 | |||
| Day High | $199.92 | P/E | N/A | |||
| Day Low | $199.92 | EPS | $-0.44 | |||
| Volume | 417,305 | |||||

